Search company, investor...
Search

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Stage

Acquired | Acquired

About iPS Cells

Provider of research to industrialize the reprogramming of human skin cells into pluripotent stem cells.

iPS Cells Headquarters Location

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest iPS Cells News

Mitsui Chemicals, Jiksak Pursue Joint Development in Aim of Commercializing Nerve Tissue Generated From Human iPS Cells

Jul 8, 2022

Set to exhibit at the Regenerative Medicine Expo (July 13–15, Tokyo Big Sight) WEBWIRE – Friday, July 8, 2022 Mitsui Chemicals, Inc. (Tokyo: 4183; President & CEO: HASHIMOTO Osamu) and Jiksak Bioengineering Inc. (Saiwai-ku, Kawasaki; CEO: KAWADA Jiro) have begun joint research aimed at commercializing Nerve Organoids™, which consist of nerve tissue derived from human iPS cells. By taking Mitsui Chemicals’ technology for InnoCell™ cell culture vessels with high oxygen permeability and combining it with Jiksak’s technology relating to the creation of Nerve Organoids™, the partners intend to develop practical technology for simply and efficiently culturing nerve tissue, which is set to become essential in the drug discovery and regenerative medicine sectors, among others. Overview of Jiksak Bioengineering Born from a NEDO startup program, Jiksak is an R&D startup company that aims to develop technologies for enabling the treatment of neurological diseases that currently lack treatment methods, such as amyotrophic lateral sclerosis (ALS). By leveraging technology that can prevent cell growth and produce nerve organoids by way of culture vessel design, Jiksak is able to provide Nerve Organoids™, which it is endeavoring to sell to drug discovery research institutes while also pursuing development aimed at use in regenerative medicine. Overview of the Nerve Organoid™ Generated from human iPS cells, a Nerve Organoid™ is nerve tissue that closely resembles an in vivo nerve, with a cell body and axon bundle (nerve). In the drug discovery process, Nerve Organoids™ can be used in more accurate testing to replace animal testing at the pre-clinical stage, on top of which there are hopes for regenerative medicine applications wherein the tissue is transplanted into the body to regenerate nerve tissue. ※Nerve Organoid™ is a trademark of Jiksak. Mitsui Chemicals’ cell culture solutions Mitsui Chemicals leverages catalyst technology, organic synthesis technology and processing technology to manufacture and sell all sorts of functional chemicals and functional resins. The company’s VISION 2030 Long-Term Business Plan includes a focus on next-generation business, where the company is aiming to bolster solutions businesses that capitalize on its R&D capabilities and assets. One strength of Mitsui Chemicals is the company’s integrated product development starting straight from material development. Mitsui Chemicals is therefore leaning on this to spur on the rollout of solutions businesses that look to solve the issues of various customers in the cell technology field, with its solutions here including culture plates; testing and drug discovery applications such as microchannel devices; and the synthesis of high-quality stem cells utilizing nonwovens. Mitsui Chemicals is also helping to cut down on the use of animal testing and animal-derived ingredients in drug discovery and food development. Overview of both companies

  • What is iPS Cells's latest funding round?

    iPS Cells's latest funding round is Acquired.

  • Who are the investors of iPS Cells?

    Investors of iPS Cells include Cellular Dynamics International.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.